Stearate-g-dextran (Dex-SA) was synthesized via an esterification reaction between the carboxyl group of stearic acid (SA) and hydroxyl group of dextran (Dex). Dex-SA could self-assemble to form nanoscaled micelles in aqueous medium. The critical micelle concentration (CMC) depended on the molecular weight of Dex and the graft ratio of SA, which ranged from 0.01 to 0.08 mg mL(-1). Using doxorubicin (DOX) as a model drug, the drug encapsulation efficiency (EE%) using Dex-SA with 10 kDa molecular weight of Dex and 6.33% graft ratio of SA could reach up to 84%. In vitro DOX release from DOX-loaded Dex-SA micelles (Dex-SA/DOX) could be prolonged to 48 h, and adjusted by a different molecular weight of Dex, the graft ratio of SA, or the drug-loading content. Tumor cellular uptake test indicated that Dex-SA micelles had excellent internalization ability, which could deliver DOX into tumor cells. In vitro cytotoxicity tests demonstrated the Dex-SA/DOX micelles could maintain the cytotoxicity of commercial doxorubicin injection against drug-sensitive tumor cells. Moreover, Dex-SA/DOX micelles presented reversal activity against DOX-resistant cells. In vivo antitumor activity results showed that Dex-SA/DOX micelles treatments effectively suppressed the tumor growth and reduced the toxicity against animal body compared with commercial doxorubicin injection.
Background:
Camptothecin (CPT) is known as an anticancer drug in traditional Chinese
medicine. However, due to the lack of targeting, low solubility, and instability of CPT, its therapeutic
applications are hampered. Therefore, we synthesized a series of CPT-bile acid analogues that obtained
a national patent to improve their tumour-targeting chemotherapeutic effects on liver or colon
cancers. Among these analogues, the compound G2 shows high antitumor activity with enhanced liver
targeting and improved oral absorption. It is significant to further investigate the possible anticancer
mechanism of G2 for its further clinical research and application.
Objective:
We aimed to unearth the anticancer mechanism of G2 in HepG2 and HCT116 cells.
Methods:
Cell viability was measured using MTT assay; cell cycle, Mitochondrial Membrane Potential
(MMP), and cell apoptosis were detected by flow cytometer; ROS was measured by Fluorescent
Microplate Reader; the mRNA and protein levels of cell cycle-related and apoptosis-associated proteins
were examined by RT-PCR and western blot, respectively.
Results:
We found that G2 inhibited cells proliferation of HepG2 and HCT116 remarkably in a dosedependent
manner. Moreover, G2-treatment led to S and G2/M phase arrest in both cells, which could
be elucidated by the change of mRNA levels of p21, p27 and Cyclin E and the increased protein level
of p21. G2 also induced dramatically ROS accumulated and MMP decreased, which contributed to the
apoptosis through activation of both the extrinsic and intrinsic pathways via changing the genes and
proteins expression involved in apoptosis pathway in both of HepG2 and HCT116 cells.
Conclusion:
These findings suggested that the apoptosis in both cell lines induced by G2 was related
to the extrinsic and intrinsic pathways.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.